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A B S T R A C T  
Objective: To find out the seropositivity of IgG rubella in pregnant women in Pakistan, to assess the prevalence of 
infection and to estimate the requirement of vaccination. 
Patients and Methods: In this retrospective cross sectional study total 730 females who visited Salma Kafeel Fertility 
Clinic (Rawalpindi) for antenatal checkup were inducted. Their age range was 18-45 years. The study was carried out 
from 2011-2016. ELISA serological testing was used to check the seroprevalence of Rubella IgG. 
Results: In total the 730 subjects were included in the study and divided in four groups according to their ages. The 
results were as follows: group 1(18-20yrs) 100% positive, group 2 (21-30yrs) 90.5% positive, group 3 (31-40yrs) 93.5% 
positive and lastly group 4 (>40yrs) 95%positive. Overall 92.32 % seropositivity was seen while 7.70% were found at risk 
of developing infection. 
Conclusion: There is a high prevalence of Rubella in females of child bearing age in Pakistan. This is alarming as it can 
result in high risk of CRS in newborns and fetal death. Therefore, women planning to become pregnant, who do not have 
natural immunity to rubella should be vaccinated at least 4 weeks prior to conception. 
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I n t r o d u c t i o n  
 
Rubella (German measles) is an acute, contagious viral 
infection. It is a generally mild condition in children, but 
may have serious consequences in pregnant women 
causing fetal deaths, or congenital defects known as 
Congenital Rubella Syndrome (CRS). The most common 
birth defects from CRS can include deafness, cataracts, 
heart problems, mental retardation, and cerebral palsy. 
Late onset manifestations of CRS include glaucoma, 
thyroiditis, and Diabetes Mellitus.1 In 1981-1983, the 
incidence of CRS in America was 0.9-1/1000.2 However, 
since 2012, only six babies with CRS have been 
reported.3 Infection with Rubella is most severe when the 
mother is infected during the first trimester of pregnancy. 
According to a study conducted in 1987, 72% of the 
married women,  77% of the pregnant females, and 
51.75% of the pre-pubertal females were immune to 
Rubella in Pakistan.4,5  
Rubella infections can be easily prevented if the adult 
women of child bearing age are vaccinated before they 
become pregnant. According to the Centers for Disease 
Control and Prevention, before the introduction of the 
measles vaccine in 1963, 4 babies in every 1000 live 
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births were born with CRS. Large scale vaccinations over 
the past decade have almost eliminated Rubella and CRS 
in the developed countries as well as in many developing 
countries. WHO Region of the America became the first in 
the world to be declared free of endemic transmission of 
Rubella in 2015.6 
In Pakistan Rubella vaccination is not the part of national 
expanded program of immunization (EPI).  Data regarding 
prevalence of Rubella antibodies among females of 
reproductive age is also insufficient. The current study is 
planned in order to find out seroprevalence of rubella 
antibodies and to high light the importance of vaccination 
in this population. 
P a t i e n t s  a n d  M e t h o d s  
The retrospective cross sectional study was carried out at 
Salma & Kafeel fertility clinic, Islamabad. Sample size 
was calculated by using open epi calculator, and 
parameters were based on 83.4% seroprevalence found 
in reproductive age with 99.9% confidence levels.7 
Calculated sample size was 600 individuals. It was a 
single center study that’s why we inducted 730 subjects to 
further strengthen our data statistically through non 
probability convenient sampling. Data of total 730 
pregnant females who visited the clinic from year 2011-
2016 for antenatal checkup was analyzed. Enzyme linked 
immunosorbent assay (ELISA) was performed to 
determine the presence of rubella specific 
immunoglobulin G (IgG). Data was entered as number 
and percentage. Chi square test was applied to determine 
the association of Rubella infection with age.  
R e s u l t s  
Total 730 subjects with age range 15-45 years were 
divided in four groups according to their ages; group 1 
(17-20 years), group 2 (21-30 years), group 3 (31-40 
years) and group 4 (40 years & above). Group 1 showed 
100% positivity while in group 2, 3 and 4 there were 
90.5%, 93.5% and 95% patients positive for Rubella IgG, 
respectively. Rubella IgG positivity shows that the women 
already had gained immunity to the infection, either 
because of previous infection or due to vaccination. The 
overall seropositivity was 92.3%, indicated the presence 
of immunity for Rubella infection and the remaining 7.70% 
females were at risk for developing Rubella infection. 
Table 1: Association of rubella infection with age 
(n=730) 
Age 
(Years) 
Patients 
(n) 
Positive 
IgG n(%) 
Negative 
IgG n(%) 
p-
value 
17-20 19 19(100) 0(0)  
 
0.000 
21-30 349 316(90.5) 33(9.5) 
31-40 319 298(93.4) 21(6.6) 
Above 
40 
43 41(95) 2(5) 
 
D i s c u s s i o n  
Rubella, also known as German measles, is a contagious 
viral disease. It is a highly infectious disease, spread via 
air through coughs of infected people. In non-pregnant 
women, it causes relatively mild symptoms such as 
coryza, low grade fever, mild redness of the eye, and an 
associated characteristic exanthematous rash. Infections 
in the pregnant women especially during the first trimester 
of pregnancy can be transmitted to the fetus, causing 
Congenital Rubella Syndrome. Congenital Rubella 
Syndrome is a major cause of several preventable life 
threatening disabilities. Ophthalmic defects, mental 
retardation, heart anomalies, sensorineural deafness are 
some common manifestations.8 There is insufficient data 
about the current immune status of pregnant women 
against Rubella in our country.  We carried out a study to 
assess the seroprevalence of Rubella IgG in pregnant 
females. IgG Serology testing can be done to diagnose 
immunity to Rubella.9 Rubella virus infection confers 
lifelong immunity but it may also be achieved through 
vaccination. Therefore, this study also helps us to 
estimate the need for Rubella vaccination among women 
in Pakistan as the MMR vaccine is not yet a part of the 
national EPI program. Although it is ideal that every 
woman of child bearing age should also be tested for 
Rubella infection and be vaccinated accordingly, at the 
very least these measures should be carried out in 
women referring to an infertility clinic. We collected data 
from 730 women seeking antenatal treatment at Salma 
and Kafeel Medical center and Infertility Services in 
Islamabad, Pakistan. Our results cannot represent the 
immune status of the entire female population of Pakistan, 
but it serves as a template for similar studies to be carried 
out in the more rural areas. The seroprevalence of 
Rubella antibodies among our study population was 
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positive for 92.32% with the remaining 7.6% testing 
negative and therefore susceptible to Rubella. The 
highest degree of susceptibility was among women of 
ages 21-30 years with a seronegativity of 4.52%, then 
susceptibility decreases with age. This means that in the 
best reproductive age (20-30 years ) considerable number 
of women if start reproduction without being immunized 
prior to conception can have a chance of getting CRS. A 
Pakistani study carried out in 2006 estimated 3 in 100 
infants as confirmed cases of Rubella. 10 
Our results are quite similar to a study conducted at 
Multan, Pakistan in females of reproductive age. Their 
study revealed 93.33% seropositivity while 5% females 
were seronegative and 3% were in intermediate range. 11 
Our results were also in concordant to a study conducted 
in 2016 at Kerala, India where 94.3% females were IgG 
positive. The mean age of the subjects (n=70) was 
24.7±4.3 years and data collection was done by ELISA. 12 
However, a cross sectional study carried out between 
2012-2014 in the district of Bijapur, showed only 31.66% 
being seropositive.13 Total 88.2% of the females, in a 
study population of 339, in Egypt were positive for Rubella 
antibodies. Immunity was higher in the 25-30 age group 
as compared to the younger 20-25 age group. 14 
In Shiraz, a city in southern Iran, a study was conducted 
to find out the seroprevalence of Anti rubella and Anti 
measles IgG in pregnant women. The results showed that 
96% were positive and immune to Rubella with mean 
geometric concentration being 14.9 IU/mL.15 This helps us 
compare our country’s immune status to other developing 
countries with an aim to collectively raise the immune 
status of these countries like that of the developed 
countries. The reported cases of Rubella in Pakistan have 
increased from 282 in 2015 to 648 in 2016. The reported 
cases in the United States was 5 in 2015 and 0 in 2016. 16 
This remarkable contrast is due to the efficient vaccination 
programs in USA. In children, the first recommended dose 
is given at 12 months of age and the second at 4 years. 
Women planning to become pregnant should be 
vaccinated at least 4 weeks prior to conception. 17 Since 
the introduction of Rubella vaccine in the Canadian 
vaccination program in 1969, the incidence of Rubella has 
had a considerable decrease with the exception of some 
outbreaks over the years. In a retrospective observational 
study conducted in Alberta in 2002-2005, 91% subjects 
tested positive. There was an increase in seronegativity 
from 8.2% in 2002 to 9.9% in 2005.18 One limitation of this 
study was convenience sampling from single center in 
main city Islamabad.  That’s why results may not fully 
represent the whole population. In future, further multi 
center studies with appropriate age and pregnancy 
duration stratification should be planned to overcome the 
bias. 
C o n c l u s i o n  
The study concludes that 7.70% females of child bearing 
age are at risk for developing rubella infection in Pakistan. 
This is alarming as it can result in high risk of congenital 
rubella syndrome in newborns and fetal deaths. It is 
suggested that women planning to become pregnant and 
don’t have natural immunity to rubella should be 
vaccinated at least 4 weeks prior to conception. 
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